Target intelligence / Profile preview

ECE1 antisense RNA 1 (ECE1-AS1)

Target: ECE1-AS1
Molecular classification: Long non-coding RNA (lncRNA), Antisense RNA

Overview

ECE1 antisense RNA 1 (ECE1-AS1) is a long non-coding antisense RNA transcribed from the opposite strand of the ECE1 gene locus. Antisense lncRNAs such as ECE1-AS1 are involved in fine-tuning the expression of their sense gene partners through mechanisms including RNA-RNA interaction, modulation of chromatin state, and influencing the stability or translation of mRNA[1][2][3][5][6]. ECE1 encodes endothelin-converting enzyme-1 (ECE-1), which is important for generating active endothelin-1, a peptide implicated in vasoregulation and cancer, but ECE1-AS1 itself does not have an enzymatic or receptor function[4]. The role of ECE1-AS1 likely includes cis-regulatory effects over the ECE1 gene, potentially impacting disease states linked to ECE1 dysregulation, although direct functional or therapeutic associations for ECE1-AS1 have yet to be conclusively reported in major scientific reviews or databases[2][5][6].

Other names: ECE1-AS1ECE1 antisense lncRNAECE1 antisense RNA 1

Mechanism of action

Not applicable, as no drugs target ECE1-AS1 directly.

Biological functions

Regulation of gene expression (typically by interacting with the sense ECE1 transcript or gene locus and modulating its expression)Epigenetic regulation (can affect chromatin structure and sense gene methylation in some cases)mRNA stability and decay (potentially via recruitment of RNA-binding proteins or RNA degradation complexes)Other (as functions of antisense lncRNAs are heterogeneous and context-dependent)

Disease associations

Cancer (Antisense lncRNAs, including ECE1-AS1, are increasingly recognized as contributors to tumor progression and may influence malignancies via regulation of neighboring protein-coding oncogenes or tumor suppressors; however, specific disease associations for ECE1-AS1 remain to be reported in prominent reviews)Other (current data on ECE1-AS1 is sparse; associations may exist based on the known function of ECE1 in cardiovascular disease and cancer[4], but not attributed to ECE1-AS1 directly in literature)

Safety considerations

None established, as it is not currently a therapeutic target.

Interacting drugs

None known. No drugs are documented to specifically target ECE1-AS1.

Biomarkers

None established. There is no evidence that ECE1-AS1 is used as a biomarker in clinical practice.

Beyond the preview

Go deeper on ECE1 antisense RNA 1 (ECE1-AS1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ECE1 antisense RNA 1 (ECE1-AS1).

Explore the full profile